Symptomdx.

Get Started

Pure Red Cell AplasiaMANAGEMENT

HEMATOLOGIC AND ONCOLOGIC PRESENTATIONS · 12 SECTIONS

⚲

757 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Acute chest syndrome Acute Hemolytic Transfusion Reaction Anticoagulant reversal (warfarin, DOAC, heparin)Aplastic Anemia (Crisis)Autoimmune Hemolytic Anemia CAR-T and cytokine release syndrome Coagulopathy Delayed Hemolytic Transfusion Reaction Disseminated Intravascular Coagulation (DIC)Essential Thrombocythemia Febrile Non-hemolytic Transfusion Reaction Graft Versus Host Disease (Acute)Hemolytic Uremic Syndrome (HUS)Hemophilia A (Bleeding Crisis)Heparin-Induced Thrombocytopenia (HIT)Hyperviscosity syndrome Immune checkpoint inhibitor toxicity Immune Thrombocytopenic Purpura (ITP)Leukemoid Reaction Leukostasis Massive transfusion protocol Myelofibrosis Neutropenic enterocolitis (typhlitis)Paroxysmal Nocturnal Hemoglobinuria Polycythemia Vera (Crisis)Pure Red Cell Aplasia Sickle Cell (Acute Chest Syndrome)Sickle Cell (Splenic Sequestration)Sickle cell crisis (vaso-occlusive)Symptomatic anemia Thrombocytopenia (severe)Thrombotic Thrombocytopenic Purpura (TTP)Transfusion-Associated Circulatory Overload (TACO)Transfusion-Related Acute Lung Injury (TRALI)Tumor lysis syndrome Von Willebrand Disease (Bleeding)

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp36

Immediate priorities

›Hemodynamic assessment for severe anemia

›Symptomatic anemia thresholds

›Hb < 7 mmol/l equivalent or < 70 g/L with symptoms

›Tachycardia, hypotension, or chest pain with anemia

›High-output cardiac failure

›Urgent transfusion indications

›Hemodynamically unstable with Hb < 60 g/L

›Angina or ECG ischemia with severe anemia

›Syncope from severe anemia

›Mean Hb at PRCA diagnosis approximately 66 g/L

›Most patients require transfusion support at presentation

›Transfuse pRBC 1 unit at a time, reassess after each unit

Escalation triggers

›Critical triggers requiring immediate action

›Hemodynamically unstable anemia

›SBP < 90 mmHg with anemia

›MAP < 65 mmHg

›Activate resuscitation bay

›Concurrent infection in immunosuppressed patient

›Fever >= 38.0 C on immunosuppressive therapy

›Empiric broad-spectrum antibiotics within 1 hour

›New anterior mediastinal mass on imaging

›Urgent thoracic surgery and oncology consultation

›Thymoma workup initiated

Immediate consults

›Consultation triggers

›Hematology — all new PRCA diagnoses

02History/hx77

Presenting symptoms

›Core anemia syndrome

›Fatigue and weakness

›Gradual onset typical — insidious progression

›Exercise intolerance as early symptom

›Dyspnea on exertion

›High-output state from severe anemia

›Orthopnea if high-output cardiac failure

›Pallor

›Conjunctival, palmar, and nail bed pallor

›Gradual appearance mirrors Hb decline

›Dizziness and syncope

›Cerebral hypoperfusion from severe anemia

›Postural component common

Onset and context

›Tempo of anemia onset

›Gradual onset over weeks to months — typical idiopathic or lymphoproliferative etiology

›Progressive transfusion dependence

›Fatigue onset often preceding diagnosis by months

›Acute onset

›Parvovirus B19 aplastic crisis in underlying hemolytic anemia

›Drug initiation timeline correlation

›Transfusion history and frequency

›Prior unexplained anemia episodes

›Escalating transfusion requirement suggesting PRCA

Risk factor history

›Underlying conditions

›Lymphoproliferative disorders

03Physical Exam/exam67

Vital signs

›Hemodynamic stability assessment

›Heart rate

›Tachycardia as high-output response to anemia

›Rate > 100 bpm with severe anemia warrants urgent transfusion consideration

›Blood pressure

›Hypotension with severe anemia is a critical finding

›SBP < 90 mmHg with Hb < 60 g/L requires immediate intervention

›Respiratory rate

›Tachypnea from high-output state or cardiac failure

›Oxygen saturation to assess cardiac reserve

›Temperature

›Fever suggests infection or underlying inflammatory trigger

›Fever on immunosuppressive therapy is urgent

Anemia findings

›Signs of anemia severity

›Pallor

›Conjunctival pallor — most sensitive sign

›Palmar crease pallor in dark-skinned patients

›Nail bed pallor

›Cardiovascular signs of high-output state

›Flow murmur — systolic ejection at left sternal border

›S3 gallop in severe high-output cardiac failure

›Bounding pulses

›Notably absent findings distinguishing PRCA from hemolytic anemia

›No jaundice — no hemolysis in PRCA

›No splenomegaly in isolated idiopathic PRCA

04Differential Diagnosis/ddx58

Life-threatening mimics

›Aplastic anemia

›ICD-10 D61.9

›Pancytopenia — all three cell lines affected

›Hypocellular marrow on biopsy (all lineages)

›Distinguished from PRCA by concurrent neutropenia and thrombocytopenia

›Myelodysplastic syndrome

›ICD-10 D46.9

›May present with PRCA morphology

›5q deletion syndrome is specific overlap

›Dysplastic changes on peripheral smear and marrow biopsy

›Acute leukemia presenting with marrow failure

›ICD-10 C91.0 / C92.0

›Blasts on peripheral smear or marrow

›Rapid onset with cytopenias

Hematologic differentials

›Large granular lymphocyte leukemia

›ICD-10 C91.2

›PRCA is a recognized complication of LGL leukemia

›Flow cytometry shows CD3+CD8+ or CD3-CD16+CD56+ LGL expansion

›TCR rearrangement studies for clonality

›CLL-associated PRCA

›ICD-10 C91.1

›Most common lymphoproliferative association

›Peripheral blood and marrow immunophenotyping

›Diamond-Blackfan anemia (congenital PRCA)

›ICD-10 D61.01

›Presents in infancy, macrocytic anemia

05Laboratory Tests/lt82

Diagnostic core labs

›Complete blood count with differential

›Normocytic normochromic anemia — hallmark finding

›MCV typically normal 80–100 fL

›WBC and platelet counts typically normal in pure PRCA

›Concurrent cytopenias suggest aplastic anemia, MDS, or LGL leukemia rather than isolated PRCA

›Neutropenia warrants urgent re-evaluation

›Thrombocytopenia indicates broader marrow failure

›Reticulocyte count

›Severely depressed — the hallmark laboratory finding in PRCA

›Absolute reticulocyte count < 10 × 10^9/L

›Reticulocyte percentage typically < 1%

›Normal reticulocyte count excludes PRCA

›Elevated reticulocyte count suggests hemolytic anemia instead

›Peripheral blood smear

›Normocytic normochromic RBCs

›No schistocytes — no hemolysis

›No spherocytes

›LGL expansion may be visible

›Large azurophilic granular lymphocytes on smear

›Confirm with flow cytometry

Etiology-directed labs

›Anti-EPO antibody testing

›Indicated when ESA response is lost in CKD patient

›Radioimmunoprecipitation assay or ELISA methods

›Positive test mandates permanent ESA discontinuation

›FDA and European guidelines recommend testing for anti-EPO antibodies before diagnosing refractory renal anemia

›Parvovirus B19 serology and PCR

›IgM and IgG antibodies

›IgM elevated in acute infection

›IgG indicates prior exposure

›Parvovirus B19 PCR — preferred in immunocompromised host

›High viral load suggests active infection

›Serology unreliable in immunocompromised due to impaired antibody production

›Viral serology panel

›HIV testing — ELISA with confirmatory Western blot

›HIV-associated PRCA

›Baseline CD4 count if positive

›EBV and hepatitis B and C serology

›Hepatitis panel prior to immunosuppressive therapy

›Reactivation risk with rituximab and other agents

›Autoimmune workup

›ANA, anti-dsDNA, complement levels

›SLE-associated PRCA

›Active lupus may require specific SLE-directed treatment

›RF and anti-CCP for rheumatoid arthritis

›Thyroid function tests

›Graves disease association

Clonality and bone marrow labs

›Flow cytometry (peripheral blood and bone marrow)

›T-cell immunophenotyping

›CD3+CD8+ LGL leukemia

›CD3-CD16+CD56+ NK-cell LGL leukemia

›B-cell markers for CLL

›CD5+CD19+CD23+ B-CLL phenotype

›STAT3 mutation testing

›Recurrently mutated in T-cell-mediated PRCA

›Present in clonal T-cell expansions

›STAT3-mutated cases may have higher immunosuppressive therapy response rates

›Next-generation sequencing for clonal hematopoiesis genes

›DNMT3A, TET2, TP53 mutations detected in approximately 62% of patients

›TP53 and DNMT3A mutations associated with worse overall survival

›Informs long-term prognosis

›Erythrocyte adenosine deaminase (eADA)

›Elevated in Diamond-Blackfan anemia

›Normal in TEC and acquired PRCA

›Key test to distinguish congenital from acquired PRCA in children

Monitoring labs during treatment

›CBC with reticulocyte count

›Reticulocyte count rises within 2–4 weeks of effective therapy

›Hemoglobin normalization may take 2–3 months

›Primary response assessment endpoint

›Frequency: every 1–2 weeks during initial treatment

›Cyclosporine trough levels

›Target trough 150–250 ng/mL

›Below target — subtherapeutic, risk of non-response

›Above target — nephrotoxicity and hypertension risk

›Monitor every 2–4 weeks until stable

›Renal function and blood pressure

›Cyclosporine nephrotoxicity monitoring

›Creatinine and eGFR

›Magnesium depletion from cyclosporine

›Ferritin

›Transfusional iron overload monitoring

›Ferritin > 1000 ng/mL threshold for iron chelation consideration

›Monitor every 1–3 months in transfusion-dependent patients

06Diagnostic Tests/dt76

Scoring Systems

›PRCA diagnostic criteria

›International consensus diagnostic criteria

›Normocytic normochromic anemia

›Absolute reticulocyte count < 10 × 10^9/L

›Bone marrow erythroid precursors < 5% with preserved granulopoiesis and megakaryopoiesis

›Anti-EPO antibody PRCA diagnostic criteria

›ESA response loss with Hb decline requiring transfusion

›Reticulocyte count < 10 × 10^9/L on ESA therapy

›Anti-EPO antibodies detected by radioimmunoprecipitation or ELISA

›Exclusion of other causes

›LGL leukemia diagnostic criteria (associated PRCA)

›LGL count > 2 × 10^9/L in peripheral blood

›T-cell or NK-cell immunophenotype on flow cytometry

›TCR gene rearrangement confirming clonality

›Present in association with cytopenias and PRCA

›Good syndrome criteria

›Thymoma plus hypogammaglobulinemia plus recurrent infections

›PRCA is a common associated finding

›Immunoglobulin levels low across all classes

MRI

›MRI chest role in PRCA

›Limited primary role in PRCA diagnosis

›CT chest is preferred first-line imaging for thymoma evaluation

›MRI rarely indicated acutely

›Problem-solving indications

›Thymoma characterization when CT findings equivocal

›Complex anterior mediastinal mass evaluation

›Distinguishing thymoma from other mediastinal pathology without radiation

›Contraindications

›Non-compatible cardiac devices or implants

›Hemodynamically unstable patient — CT preferred

›MRI bone marrow

›Bone marrow fat signal changes with aplasia

›Increased fat signal on T1 with erythroid aplasia

›Research application rather than routine clinical tool

›Rarely used in favor of direct bone marrow biopsy

›CT chest with contrast

›First-line imaging for thymoma evaluation in all new PRCA diagnoses

›Thymoma found in 10–22% of PRCA patients

›Conversely 2–5% of thymoma patients develop PRCA

›Anterior mediastinal mass characterization

›Mediastinal lymphadenopathy

›Lymphoproliferative disorder evaluation

›Lymphoma staging considerations

›Protocol

›IV contrast preferred for mediastinal mass evaluation

›Coronal and sagittal reconstructions for surgical planning

›CT abdomen and pelvis with contrast

›Lymphadenopathy evaluation

›Retroperitoneal and mesenteric nodes

›CLL or lymphoma staging

›Hepatosplenomegaly

›Lymphoproliferative disorder extent

›Baseline splenic volume

›PET-CT

›Indicated when malignancy or active lymphoma suspected

›Staging of newly diagnosed lymphoproliferative disease

›FDG avidity differentiates active disease from treated disease

Ultrasound

›Abdominal ultrasound

›Splenomegaly assessment

›Enlarged spleen suggests lymphoproliferative disorder

›Absent in isolated idiopathic PRCA

›Hepatomegaly evaluation

›Liver infiltration by lymphoma or CLL

›Iron overload hepatomegaly from chronic transfusions

›Lymph node sampling guidance

›Ultrasound-guided lymph node biopsy for lymphoma diagnosis

›Cardiac echocardiography

›High-output cardiac failure assessment

›Elevated cardiac output with severe anemia

›Dilated cardiomyopathy from iron overload in transfusion-dependent patients

›Baseline cardiac function before anthracycline-based therapy

›If chemotherapy required for underlying malignancy

›Point-of-care ultrasound

›IVC assessment for fluid status in acute presentation

›Guides transfusion and resuscitation in unstable patient

›Not PRCA-specific — general critical care assessment

07Disposition/dispo38

Admission criteria

›Hospital admission indications

›Symptomatic severe anemia requiring urgent transfusion

›Hb < 60 g/L with tachycardia, hypotension, or chest pain

›Syncope or presyncope from anemia

›High-output cardiac failure

›Hemodynamic instability

›SBP < 90 mmHg

›Lactate elevation suggesting organ hypoperfusion

›New diagnosis requiring expedited inpatient workup

›Bone marrow biopsy scheduling

›Urgent hematology consultation

›Severe infection in immunosuppressed patient

›Fever on cyclosporine or other immunosuppressants

›Sepsis evaluation

›Thymoma requiring surgical planning

›Oncology and thoracic surgery coordination

ICU indications

›Critical care admission triggers

›Hemodynamic collapse from severe anemia

›Vasopressor support requirement

›Cardiac ischemia from demand

›Septic shock in immunocompromised PRCA patient

›Volume resuscitation and vasopressor initiation

›Infectious disease consultation

Outpatient management criteria

›Safe for outpatient management

›Stable Hb with asymptomatic anemia

08Treatment/t104

Immediate stabilization

›RBC transfusion support

›Packed red blood cells

›Transfuse for Hb < 70–80 g/L with symptoms

›Leukoreduced blood products preferred

›CMV-negative products for CMV-negative immunocompromised patients

›Transfusion rate

›1 unit pRBC over 2–4 hours in stable patient

›Slower rate if cardiac failure risk (1 unit over 4 hours with furosemide 20–40 mg IV)

›Transfusion target

›Hb 80–90 g/L in symptomatic patients

›Hb 70–80 g/L in asymptomatic stable patients

Etiology-specific treatment

›Drug-induced PRCA

›Discontinue offending agent immediately

›PRCA may resolve spontaneously after drug cessation

›Antiepileptics, azathioprine, procainamide, chloramphenicol

›Anti-EPO antibody PRCA

›Permanently discontinue all ESA products — no re-exposure

›FDA label mandates permanent ESA cessation for confirmed anti-EPO antibody PRCA

›Do NOT switch to a different ESA product — cross-reactivity occurs

›Parvovirus B19-associated PRCA

›Intravenous immunoglobulin

›IVIG 0.4 g/kg/day IV for 5 days

›Repeat courses if relapse in immunocompromised

›Highly effective for parvovirus B19 PRCA and hypogammaglobulinemia-associated cases

›Thymoma-associated PRCA

›Thymectomy for underlying thymoma

›Thymectomy alone rarely curative for PRCA

›Immunosuppressive therapy typically required post-thymectomy

›Relapse rate 54% in thymoma-associated PRCA

›Combined thymectomy plus immunosuppression

›Standard approach for thymoma-associated PRCA

›Sirolimus shows 50% response in refractory thymoma-associated cases

First-line immunosuppressive therapy

›Cyclosporine A (CsA) as first-line — overall response rate 70–76%

›CsA dosing

›3–5 mg/kg/day orally in divided doses every 12 hours

›Target trough level 150–250 ng/mL

›Adjust dose based on trough levels and renal function

›CsA plus corticosteroids combination — highest efficacy, ORR approximately 76%

›Prednisone 1 mg/kg/day (max 60 mg) with slow taper

›Taper prednisone over 4–6 weeks once reticulocyte response achieved

›Response assessment at 2–3 months

›Reticulocyte count rise within 2–4 weeks of effective therapy

›Hb normalization may take 2–3 months

›Duration of CsA

›Continue for minimum 6–12 months after response

›Premature CsA discontinuation leads to high relapse rates

›Corticosteroids alone (initial ORR 67–77%, but frequent relapse on taper)

›Prednisone 1 mg/kg/day orally

›Maximum 60 mg/day

›Taper over 3–6 months once response achieved

›Corticosteroids less durable than CsA for long-term remission

›Relapse common on taper

›Add CsA for steroid-relapsing cases

Second-line and salvage therapy

›Oral cyclophosphamide

›Second-line option — lower response rate than CsA

›50–100 mg/day orally

›Monitor CBC for myelosuppression

›Bladder toxicity — ensure adequate hydration

›Alemtuzumab

›Particularly effective for LGL leukemia-associated PRCA

›10–30 mg IV or SC, protocols vary

›PJP prophylaxis required during and after therapy

›CMV monitoring required

›Rituximab

›B-cell-mediated or CLL-associated PRCA

›375 mg/m2 IV weekly for 4 doses

›Hepatitis B reactivation risk — screen and prophylax if HBsAg positive

›Anti-thymocyte globulin (ATG)

›Horse ATG (hATG) 40 mg/kg/day IV for 4 days

›Premedicate with methylprednisolone 1 mg/kg and diphenhydramine

›Serum sickness monitoring from day 7–14

›Bortezomib

›Role in refractory idiopathic or antibody-mediated PRCA

›1.3 mg/m2 SC on days 1, 4, 8, 11

›Neuropathy monitoring required

›Sirolimus (rapamycin)

›50% response rate in refractory thymoma-associated PRCA

›2–5 mg/day orally targeting trough 5–15 ng/mL

›Monitor for mucositis, hyperlipidemia, and wound healing

›Daratumumab

›Promising in post-HSCT ABO-mismatched PRCA

›16 mg/kg IV weekly for 8 weeks then every 2 weeks

›Pre-medication required to reduce infusion reactions

›Allogeneic HSCT

›Potentially curative for refractory PRCA

›Significant transplant-related mortality — reported 4 of 8 patients died within 3 months in one series

›Reserved for young patients with refractory disease and no comorbidities

ESA replacement in CKD-PRCA

›Roxadustat (HIF-prolyl hydroxylase inhibitor)

›Emerging evidence for anti-EPO antibody PRCA in CKD patients

›Stimulates endogenous EPO pathway independent of exogenous EPO

›Not cross-reactive with anti-EPO antibodies

›Dosing

›Weight-based dosing: 70–200 mg orally three times weekly

›Titrate to Hb target 100–120 g/L

›Caution

›Thromboembolic risk monitoring required

›Hypertension monitoring

Iron overload management

›Iron chelation therapy

›Indicated when ferritin > 1000 ng/mL in chronically transfused patients

›Deferoxamine 20–40 mg/kg/day SC infusion over 8–12 hours

›Deferasirox 14–28 mg/kg/day orally once daily

›Avoid unnecessary iron supplementation

›Increased iron stores already seen on bone marrow biopsy in PRCA

›Iron supplementation may worsen iron overload without benefit

09Special Populations/sp68

Pregnancy

›Pregnancy and PRCA considerations

›Rare association between pregnancy and PRCA

›Case reports of pregnancy-associated PRCA typically resolving postpartum

›Mechanism possibly immune-mediated or hormonal

›Anemia management in pregnancy

›RBC transfusion for symptomatic severe anemia — same thresholds

›Leukoreduced and CMV-negative blood products preferred in immunocompromised

›Medication safety in pregnancy

›Cyclosporine — Pregnancy Category C, use with caution when benefit outweighs risk

›Corticosteroids — generally considered compatible with pregnancy with monitoring

›Cyclophosphamide — teratogenic in first trimester, avoid

›Rituximab — avoid in pregnancy; fetal B-cell depletion risk

›ESA and pregnancy

›ESA use in pregnancy requires individualized risk-benefit assessment

›Anti-EPO antibody PRCA in pregnancy mandates ESA cessation regardless

›Fetal monitoring

›Fetal wellbeing assessment with severe maternal anemia

›Obstetric consultation for all pregnant patients with PRCA

›Postpartum consideration

›Pregnancy-associated PRCA may resolve postpartum

›Monitor CBC closely in postpartum period

Geriatric

›Geriatric considerations

›Higher prevalence of underlying lymphoproliferative disorders

›CLL and LGL leukemia more common in older adults

›Comprehensive geriatric assessment before immunosuppression initiation

›Cyclosporine use in elderly

›Increased nephrotoxicity risk with age-related reduced GFR

›Start at lower end of dosing range: 3 mg/kg/day

›More frequent renal function monitoring — every 2 weeks initially

›Drug interactions with common geriatric medications (calcium channel blockers, statins)

›Corticosteroid toxicity in elderly

›Osteoporosis risk — ensure calcium 1200 mg/day and vitamin D 800–1000 IU/day supplementation

›Fracture risk assessment

›Hyperglycemia monitoring — glucose twice daily in diabetic patients

›Delirium risk from high-dose steroids

›Infection risk

›Infection is the major cause of mortality from immunosuppressive therapy

›Pneumocystis jirovecii pneumonia (PJP) prophylaxis with TMP-SMX or dapsone

›Herpes zoster reactivation risk — acyclovir 400 mg twice daily prophylaxis

›Transfusion considerations in elderly

›Cardiac reserve reduced — slower transfusion rate

›1 unit pRBC over 4 hours with concurrent furosemide 20 mg IV if systolic dysfunction

›Avoid over-transfusion above Hb 90 g/L

Pediatrics

›Pediatric PRCA distinctions

›Diamond-Blackfan anemia (congenital PRCA)

›Presents in infancy (median age 2–3 months)

›Macrocytic anemia with reticulocytopenia

›Elevated eADA — distinguishes from acquired PRCA

›Physical anomalies (thumb, craniofacial, cardiac) in approximately 50%

›Managed with corticosteroids, transfusions, or HSCT

›Transient erythroblastopenia of childhood (TEC)

›Self-resolving, typically age 6 months to 5 years

›Normal eADA — distinguishes from DBA

›Normocytic anemia with reticulocytopenia, then recovery

›No treatment required — supportive care and monitoring only

›Recovery within 1–2 months in most cases

›Parvovirus B19 in children with hemolytic anemias

›Sickle cell disease, hereditary spherocytosis — aplastic crisis risk

›IVIG 0.4 g/kg/day for 5 days in immunocompromised

›Self-limited in immunocompetent children

›Immunosuppressive therapy in pediatric acquired PRCA

›Corticosteroids first-line for acquired pediatric PRCA

›Prednisone 1–2 mg/kg/day orally (max 60 mg/day)

›CsA for steroid-refractory cases — dose 3–5 mg/kg/day with trough monitoring

›Transfusion in children

›pRBC 10–15 mL/kg for each transfusion episode

›Leukoreduced irradiated blood products for immunocompromised children

›Hb target 70–80 g/L for stable, 80–90 g/L if symptomatic

10Background/b89

Epidemiology

›Incidence and prevalence

›Estimated annual incidence approximately 1.06 per million

›Rare bone marrow failure syndrome

›True prevalence likely underestimated due to underdiagnosis

›Age distribution

›Acquired PRCA predominantly affects adults over 50 years

›Diamond-Blackfan anemia presents in infancy

›TEC affects children 6 months to 5 years

›Sex distribution

›No strong sex predilection in idiopathic acquired PRCA

›LGL leukemia-associated PRCA slightly more common in females

›Etiology distribution

›Approximately 50% of cases are idiopathic

›Presumed autoimmune mechanism

›Primary immune-mediated PRCA

›Secondary causes account for remaining 50%

›Lymphoproliferative disorders: most common secondary cause

›LGL leukemia: leading single hematologic cause

›Thymoma: 10–22% of PRCA patients

›Autoimmune diseases: SLE, RA, myasthenia gravis

›Infections: parvovirus B19, HIV, EBV, hepatitis, COVID-19

›Drugs: ESAs, antiepileptics, azathioprine, chloramphenicol

›Post-HSCT ABO mismatch: incidence 10–30%

›Prognosis

›Median overall survival for primary PRCA > 10 years

›Japanese nationwide cohort: median OS not yet reached for idiopathic PRCA

›Thymoma-associated PRCA: median OS approximately 142 months

›LGL-associated PRCA: median OS approximately 148 months

›Relapse is common

›56% of responders relapse in some series

›Median of 2 different therapies needed to achieve remission

›Infection is the major cause of morbidity and mortality from immunosuppression

›Higher somatic mutation burden associated with worse outcomes

›TP53 and DNMT3A mutations — worse overall survival

›STAT3 mutations — associated with T-cell-mediated PRCA

Pathophysiology

›Immune-mediated erythroid suppression

›T-cell-mediated mechanism — primary pathogenic pathway

›Autoreactive cytotoxic CD8+ T cells targeting erythroid precursors

›Polyclonal to monoclonal T-cell expansion continuum

›STAT3 mutations mark clonal T-cell populations

›Clonal T-cell expansion detected in approximately 62% of patients by NGS

›Antibody-mediated mechanisms

›Anti-EPO antibodies in ESA-associated PRCA

›Antibodies neutralize both exogenous and endogenous EPO

›Anti-erythroblast antibodies in some idiopathic cases

›HLA associations

›HLA-B46:01 and HLA-DRB1 09:01 associated with anti-EPO antibody PRCA

›Particularly in Asian populations

›Bone marrow findings

›Selective absence or marked reduction of erythroid precursors

›< 5% erythroid precursors on marrow biopsy

›Preserved granulopoiesis and megakaryopoiesis — distinguishes from aplastic anemia

›Normocellular or hypocellular marrow (erythroid component only)

›Parvovirus B19-specific marrow findings

›Giant proerythroblasts with intranuclear viral inclusions

›Pathognomonic when present

›Increased iron stores

›Iron deposition from absent erythroid utilization

›Worsened by chronic transfusion dependence

›Parvovirus B19 mechanism

›P antigen receptor on erythroid progenitors

›Viral binding causes cytolysis of erythroid precursors

›Immunocompetent — self-limited aplastic crisis lasting 10–14 days

›Immunocompromised — persistent replication and chronic PRCA

Therapeutic Considerations

›Immunosuppression rationale

›T-cell suppression is primary treatment goal

›Cyclosporine suppresses T-cell activation by calcineurin inhibition

›Corticosteroids broadly suppress immune activation

›CsA plus corticosteroids superior to either alone — ORR approximately 76%

›Duration and relapse

›Premature cessation of CsA leads to high relapse rates

›Long-term maintenance therapy often required

›56% relapse rate means repeat courses are common

›Etiology determines treatment strategy

›Parvovirus B19 — IVIG, not immunosuppression

›Immunosuppression would worsen viral replication

›Anti-EPO antibody PRCA — permanent ESA cessation plus immunosuppression

›No ESA re-exposure ever — class effect, all ESA products contraindicated

›LGL leukemia-associated — alemtuzumab most effective

›Targets CD52-expressing LGL cells

›Post-HSCT PRCA — donor lymphocyte infusion or daratumumab

›Targets residual host anti-donor antibodies

›Treatment sequencing

›Median of 2 therapies needed before remission in refractory cases

›First relapse or refractoriness — second-line immunosuppression

›Allogeneic HSCT reserved for highly refractory cases

›Iron chelation is a parallel therapeutic priority

›Transfusional iron overload is preventable cause of end-organ damage

›Early chelation when ferritin > 1000 ng/mL

11Patient Discharge Instructions/pdi36

copy discharge instructions

›Pure Red Cell Aplasia home care instructions

›Follow all hematologist appointments closely — this condition requires specialist management

›Take all prescribed medications exactly as directed

›Do not stop cyclosporine or prednisone without speaking to your doctor first — stopping suddenly may cause relapse

›Medication precautions at home

›Cyclosporine — take at the same time each day for consistent blood levels

›Do not take with grapefruit juice — it raises drug levels

›Common side effects: tremor, gum swelling, increased hair growth, high blood pressure

›Prednisone — take with food to protect stomach

›Do not suddenly stop without medical guidance

›Side effects include weight gain, elevated blood sugar, mood changes, bone thinning

›Report any new medications to your hematologist — drug interactions are common

›Infection precautions while on immunosuppression

›Avoid contact with sick individuals

›Wash hands frequently

›Avoid raw or undercooked foods

›Fever of 38.0 C or higher while on immunosuppression requires immediate medical attention

›Activity and diet

›Limit strenuous activity until hemoglobin has improved and hematologist approves

›Adequate folate and B12 intake to support red blood cell recovery

›Avoid unnecessary iron supplements unless instructed by your doctor

›Warning signs — return to emergency department immediately for

›Worsening fatigue, dizziness, or fainting

›Chest pain or pressure

›Shortness of breath at rest or with minimal activity

›Fever at or above 38.0 C (100.4 F) on immunosuppressant therapy

›Rapid heart rate or palpitations

12References/r26

Guidelines and key sources

›Guideline and consensus sources

›Gurnari C, Maciejewski JP. How I Manage Acquired Pure Red Cell Aplasia in Adults. Blood. 2021

›Means RT. Pure Red Cell Aplasia. Blood. 2016

›Sawada K, Fujishima N, Hirokawa M. Acquired Pure Red Cell Aplasia: Updated Review of Treatment. British Journal of Haematology. 2008

›Balasubramanian SK et al. Rational Management Approach to Pure Red Cell Aplasia. Haematologica. 2018

›Key clinical studies

›Yusup M et al. Efficacy and Influencing Factors of Immunosuppressive Therapy for PRCA: Meta-Analysis. Annals of Hematology. 2025

›Hirokawa M et al. Long-Term Outcome of Patients With Acquired Chronic PRCA Following Immunosuppressive Therapy. British Journal of Haematology. 2015

›Hemmer M et al. Pure Red Cell Aplasia Associated With Thymic Tumors, a Nationwide Retrospective Study. American Journal of Hematology. 2025

›Wu X et al. Clinical Characteristics and Outcomes of 100 Adult Patients With Pure Red Cell Aplasia. Annals of Hematology. 2022

›Anti-EPO antibody PRCA references

›Casadevall N et al. Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin. NEJM. 2002

›Bennett CL et al. Pure Red-Cell Aplasia and Epoetin Therapy. NEJM. 2004

›Casadevall N et al. Recommendations on haematological criteria for the diagnosis of epoetin-induced PRCA. European Journal of Haematology. 2004

›Devathasan J et al. A Rising Cluster of Erythropoietin-Associated PRCA and Subsequent Response to Roxadustat. Nephrology. 2026

›Post-HSCT and specialized PRCA references

›Desai N et al. Daratumumab in the Management of Red Cell Aplasia Following Allogeneic HSCT. European Journal of Haematology. 2025

›Metafuni E et al. Pure Red Cell Aplasia Among ABO Mismatched HSCT Recipients. Frontiers in Oncology. 2024

›Noguchi Y et al. Outcomes of Allogeneic HSCT for Acquired Pure Red Cell Aplasia. International Journal of Hematology. 2026

›Genomic and molecular references

›Yang L et al. Somatic Mutations and Mutation Burden Predict Treatment Response and Survival in Adult Acquired PRCA. American Journal of Hematology. 2026

›Kawakami F et al. T Cell Clonal Expansion and STAT3 Mutations in Acquired Chronic T Cell-Mediated PRCA. International Journal of Hematology. 2022

›Suttichet TB et al. HLA-B46:01 and HLA-DRB1 09:01 Are Associated With Anti-rHuEPO-Induced PRCA. Scientific Reports. 2023

›Congenital PRCA references

›Sieff C. Diamond-Blackfan Anemia Syndrome. GeneReviews. 2025

›Clark DA et al. Studies on Pure Red Cell Aplasia XI. Results of Immunosuppressive Treatment of 37 Patients. Blood. 1984

Learn More: Pure Red Cell Aplasia→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.